Gatralimab - CAS 1826020-80-7

Gatralimab (GZ-402668) is a next-generation humanized anti-CD52 monoclonal antibody for which phase 1 clinical trial data indicate it successfully achieves the intended pharmacodynamic effect of lymphocyte depletion followed by subsequent repopulation, all with an acceptable safety profile, supporting its further investigation about relapsing-remitting multiple sclerosis (MS) .

NF-κB

NF-κB

1825933

0.9975

-20°C

Ice Packs

Inhibitory Antibodies